The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $20.27

Today's change0.00 0.00%
Updated June 29 4:00 PM EDT. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $20.27

Today's change0.00 0.00%
Updated June 29 4:00 PM EDT. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc closed at (U.S.)$20.27.

Over the last five days, shares have lost 6.33% and are down 80.06% for the last year to date. This security has underperformed the S&P 500 by 91.44% during the last year.

Key company metrics

  • Open(U.S.) $20.30
  • Previous close(U.S.) $20.27
  • High(U.S.) $20.50
  • Low(U.S.) $19.64
  • Bid / Ask-- / --
  • YTD % change-80.06%
  • Volume17,599,930
  • Average volume (10-day)22,806,328
  • Average volume (1-month)29,164,366
  • Average volume (3-month)31,937,787
  • 52-week range(U.S.) $18.55 to (U.S.) $263.81
  • Beta0.33
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward3.06×
  • Forward PEG0.40×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$2.14
Updated June 29 4:00 PM EDT. Delayed by at least 15 minutes.
S&P TSX1.40%Sector:Industry:

Latest Company News

View more News
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue2,3722,7362,7872,732
Total other revenue--------
Total revenue2,3722,7362,7872,732
Gross profit1,7422,0602,1392,047
Total cost of revenue630677648685
Total operating expense2,3052,5422,3392,391
Selling / general / administrative813743698686
Research & development1039610281
Depreciation / amortization695789679585
Interest expense (income), net operating--------
Unusual expense (income)42195182177
Other operating expenses, total234330177
Operating income66195448342
Interest income (expense), net non-operating-427-433-420-413
Gain (loss) on sale of assets--------
Other--------
Income before tax-366-240-6-65
Income after tax-373-36252-52
Income tax, total7122-57-13
Net income-374-36250-53
Total adjustments to net income--------
Net income before extra. items-374-36250-53
Minority interest-11-2-1
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-374-36250-53
Inc. avail. to common incl. extra. items-374-36250-53
Diluted net income-374-36250-53
Dilution adjustment----00
Diluted weighted average shares345348351344
Diluted EPS excluding extraordinary itemsvalue per share-1.08-1.040.14-0.15
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.00-0.540.570.19